Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab Long-Term Extension in Alzheimer's Disease
NCT00606476Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2006
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Dec 2006; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00606476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606476.